The immunoblotting study indicates that upregulation of the mevalonate pathway enzyme HMGCS1 in serum-deprived cancer cells was prevented by the mTOR kinase inhibitor Torin 1 (Figure 7). This evidence concerns the gene HMGCS1 and cancer.